IMI AMR Accelerator

GARDP Live Webinar: Influence of biological sex in infectious disease
2022-12-13 15:30 - 17:00 (Europe/Berlin) | Online
This live webinar includes an interactive Q&A session and will be broadcast on 13 December 2022 at 15:30 – 17:00 CET. Find your time zone here. For more information and to register please visit the website.

Communication Training for Scientists in the AMR Accelerator (AMR Accelerator Members only)
2022-12-08 11:00 - 12:30 (Europe/Berlin) | Online

Science Interest Group on Animal Models - Kick-off Meeting (AMR Accelerator Members only)
2022-12-06 | Online
About fifteen people attended the kick-off meeting of the Scientific Interest Group (SIG) on animal models. First, all attendees introduced themselves and outlined which models they currently use in their project. Frederik Deroose, SIG Chairman, Connecting Pharma (ex-Asclepia Outsourcing Solutions), SIG Chairman and Carina Vingsbo Lundberg, SIG Leader, Statens Serum Institut introduced the Animal Models Scientific Interest Group (SIG) and its charter. Carina gave an expert talk on “Standardisation of Pneumonia Models”, which was followed by a presentation by Yojana Gadiya, Fraunhofer ITMP on the AMR Knowledge Graph, a novel data resource and innovative visualisation tool built at Fraunhofer ITMP and available to the AMR Accelerator. The second part of the meeting was focused on what this group is expecting from this SIG, and Frederik Deroose ended the meeting with a summary and outline of the next steps and action points.

Machine Learning Science Interest Group Kick-off Meeting (AMR Accelerator Members only)
2022-11-30 13:30 - 15:00 (Europe/Berlin) | Online
About fifteen people attended the kick-off meeting of the Scientific Interest Group (SIG) on machine learning (ML). First, all attendees introduced themselves and outlined their interest in ML. Frederik Deroose, SIG Chairman, Connecting Pharma (ex-Asclepia Outsourcing Solutions) and Philip Gribbon, SIG Leader, Fraunhofer ITMP introduced the ML Scientific Interest Group (SIG) and its charter. Daniel Domingo-Fernandez, Fraunhofer SCAI and Andrea Zaliani, Fraunhofer ITMP gave expert talks on ML applications in drug discovery and ML-based age predictions based on human methylomes. The talks were followed by a presentation by Yojana Gadiya, Fraunhofer ITMP on the AMR Knowledge Graph and CoADD data sets. The second part of the meeting was focused on what this group is expecting from this SIG, and Frederik Deroose ended the meeting with a summary and outline of the next steps and action points.

ERA4TB Webinar on Challenges of tuberculosis (TB) drug development and access – clinical, regulatory and HTA perspectives
2022-11-24 11:00 - 12:15 (Europe/London) | Online
ERA4TB launched a series of webinars aimed at exploring key topics in relation to tuberculosis and antimicrobial research and development from clinical, regulatory and HTA perspectives.
With the title “Challenges of tuberculosis (TB) drug development and access – clinical, regulatory and HTA perspectives”, the first webinar was held on 24th November 2022, 11.00-12.15 GMT coinciding with World Antimicrobial Awareness Week.
The session hosted the following experts in the field, particularly:

Francesca Conradie, prominent TB researcher and clinician at the University of Witswatersrand, and ERA4TB Scientific Advisory Board member, who will discuss the current and emerging clinical challenges to tuberculosis and how these are and will influence drug development needs.
Sophie Cooper, Senior Scientific Advisor at the National Institute for Health and Care Excellence (NICE) who will provide an overview of NICE’s work to tackle antimicrobial resistance through new payment models.

This event was being hosted by our partner organisation, NICE.
Please contact Katharine.Cresswell@nice.org.uk if you require any further information.

Uppsala Antibiotic Days Conference
2022-11-24 - 2022-11-25 | Uppsala, Sweden, Uppsala University Main Building, Biskopsgatan 3, Uppsala, 753 10, Sweden
The Uppsala Antibiotic Days conference has been established with the goal of creating a forum to support scientific exchange amongst local, national and international experts on antimicrobial resistance (AMR). There is consensus that AMR constitutes a multifaceted issue which poses a substantial threat to the health and prosperity of communities worldwide. As experts on this topic, we recognize that any tangible and lasting solution to this so-called “silent pandemic” will require expertise from an equally multidisciplinary faculty.

Uppsala’s unique position as a European hub for research and innovation, in particular AMR, makes the city an excellent venue where scientists, clinicians, and members of the public can gather to share meaningful ideas about the topic. We encourage attendees to submit abstracts for the opportunity to present their scientific discoveries. While the conference’s primary directive leans towards those working directly within the field, we also welcome members of the broad scientific community and general public who wish to participate in the discussion.
Conference programme
Registration

World Antimicrobial Awareness Week
2022-11-18 - 2022-11-24 | Globally
Celebrated annually, the World Antimicrobial Awareness Week (WAAW) aims to increase awareness of global antimicrobial resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of drug-resistant infections.

Emerging Antimicrobials and Diagnostics in AMR 2022
2022-11-18 | Online
EADA 2022 will provide an international podium for emerging preventives, antimicrobial strategies, microbial diagnostics and related (platform) technologies.

International Congress on Infectious Diseases 2022
2022-11-17 - 2022-11-20 | Kuala Lumpur, Malaysia
The International Society for Infectious Diseases (ISID) will hold its next in-person and virtual International Congress on Infectious Diseases November 17–20, 2022 in Kuala Lumpur, Malaysia in collaboration with the Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC).
The ISID Congress is the leading Infectious Disease conference that convenes clinicians, allied health professionals, and scientists to share world-class expertise to address global challenges. This unique event focuses on clinical practice, basic and translational science, novel approaches to infection control and prevention, epidemiology of infectious diseases, and much more.

The UNION World Conference on Lung Health
2022-11-08 - 2022-11-11 | Online, RI
Theme for 2022: COMBATING PANDEMICS – TODAY & TOMORROW: We must work together towards the elimination of all lung health pandemics and this can only be achieved if we address the issues of equity and inclusion for a healthier, safer world. Whether it is COVID-19 or Tuberculosis (TB), lung health pandemics continue to cause havoc the world over, exposing inequalities while also revealing how interconnected we truly all are. As we work towards averting future pandemics, we must not forget existing pandemics like TB and ensure we serve those who are most vulnerable.

2022 Antimicrobial Resistance Conference
2022-11-02 14:00 - 21:00 (Europe/Berlin) | Digital event
Please save the date for the 2022 Antimicrobial Resistance Conference organised by Infoma Connect.
Conference theme: ACT NOW: INCENTIVES & STRATEGIES TO DRIVE INNOVATION IN THE ANTIMICROBIAL RESISTANCE MARKET.
Topics:
– Improve Government Funding.
– Reform Reimbursement Schemes.
– Promote Surveillance and Stewardship Programmes.
– Discover and Develop Drugs and Novel Technology.
See the full agenda here

ESCMID/ASM Conference 2022
2022-10-04 - 2022-10-07 | Crowne Plaza Dublin, Blanchardstown Town Centre, Dublin, Dublin, 15, Ireland
Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by national and international bodies. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development to address antimicrobial resistance.

Tuberculosis, current status update from ongoing research collaborations within the AMR Accelerator (AMR Accelerator Members only)
2022-09-13 15:00 - 16:30 (Europe/Berlin) | Online
About twenty people attended this webinar which focused on some highlights and challenges from three TB focused projects, namely UNITE4TB, ERA4TB, and TRIC-TB. The selected speakers, Modesto Remuinan-Blanco (TRIC-TB and GSK), Martin Boeree (UNITE4TB and Radboud UMC), Alfonso Mendoza-Losana (ERA4TB and Universidad Carlos III Madrid) and Oscar della Pasqua (ERA4TB and Consiglia Nazionale delle Ricerche) shared some of the challenges they have been facing within their projects and how they are addressing these. In the last part of this webinar, Frederik Deroose (Connecting Pharma) hosted a panel with whom he discussed and addressed the scientific challenges of the TB research as a global area of interest.

EMBO Workshop on Tuberculosis 2022
2022-09-12 - 2022-09-16 | CIS, 25-28 Rue du Dr Roux,, Paris, Paris, 75015, France
The EMBO Workshop on Tuberculosis 2022, originally planned for September 2020 and postponed to 2022 due to the Covid-19 pandemic, has recently received again the support from EMBO, and is now scheduled to be held from September 12-16, 2022 at the Conference Centre (CIS) of the Institut Pasteur in Paris.
The EMBO Workshop on Tuberculosis 2022 will be the 3rd congress on tuberculosis (TB) and pathogenic mycobacteria in the CIS of the Institut Pasteur in the 21st century, following the previous two very successful EMBO-sponsored congresses held in 2012 and 2016 at the same location, which included more than 500 scientists at each meeting.

2022 World Anti-Microbial Resistance Congress
2022-09-07 - 2022-09-08 | Gaylord National Resort & Convention Center, 201 Waterfront Street, National Harbor, MD, 20745, United States
Since 2015, the World Antimicrobial Resistance Congress has attracted top thought leaders, hospitals, companies, and policymakers as the annual, go-to event in the Antimicrobial Resistance (AMR) space. We have grown into the most impactful event in advancing solutions to combat this pressing global health crisis. Diagnostic developers, antibiotic biotechs & pharmaceutical companies, stewardship technologies, access firms, and many more, rely on our event for business development opportunities, networking and showcasing of new products and solutions. With over 1,300+ attendees, the 2022 conference will be a must-attend for any companies looking to:

Showcase & learn about new antibiotic and non-traditional products
Demonstrate how new diagnostic technologies can reduce time to accurate diagnosis and support the appropriate use of antibiotics
Meet with top hospitals from around the world
Network with key policymakers, organizations, regulators to further AMR policies
Interact with funding agencies, investors and venture capitalist firms
Introduce the most innovative stewardship and infection control technologies for the hospitals
Learn more about sustainable antibiotic manufacturing practices
Engage in conversations around one-health and vaccines and their relationships with AMR

Register here

REVIVE Webinar: Challenges of developing antibiotic combinations
2022-08-23 17:00 - 18:30 (Europe/Berlin) | Online
On 23 August, Michael N. Dudley and Glenn Dale will discuss the Challenges and options in developing antibiotic combinations.

Animal models to study the activity of antibiotics
2022-08-10 17:00 - 18:30 (Europe/Berlin) | Online
In this webinar, the speakers will discuss will provide an overview of basic animal models and explain the basis for their selection and limitations for specific situations and needs to study the activity of antibiotics. The speakers will give the following presentations: – Overview of common animal models (Lynn Miesel) – Zebrafish larvae as an early in vivo model in antibiotic drug discovery (Jennifer Herrmann) Audience questions will be answered at the end of the webinar.

Speakers:
– Lynn Miesel, Pharmacology Discovery Services Ltd, USA
– Jennifer Herrmann, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany

Moderator:
– William Hope, University of Liverpool (UK)

REVIVE Webinar: New approaches to antibiotic discovery
2022-07-26 16:00 - 17:30 (Europe/Berlin) | Online
On 26 July, James J. Collins and Richard Lee will be discussing the use of Synthetic biology and interdisciplinary approaches for antibiotic discovery.

COMBINE Poster Presentations at the Gordon Research Conference on Disruptive Antibiotics and Non-Antibiotic Therapies to Combat Drug-Resistant Bacterial Infections
2022-07-24 - 2022-07-29 | In-person, Lucca, Italy
The prosperity of the modern world is threatened by the emergence of drug resistant pathogens, pesticide-resistant insects and herbicide-resistant weeds. Novel investigational cancer drugs increase life expectancy, but fail when resistance develops. The same principles of evolution drive the development of resistance in all of these contexts, yet each field attacks the problem of resistance alone. The Drug Resistance Gordon Research Conference (DRGRC) provides a unique forum where scientists and physicians working in infectious diseases, cancer and agriculture come together to discuss common issues and share approaches with the conviction that general strategies to minimize resistance can be developed by working together.
As in previous years, the conference strives to recruit a broad array of disciplinary expertise, varying seniority, and wide geographic and cultural perspectives. The organizers are recruiting internationally recognized speakers from infectious disease, cancer and agriculture, including representatives from academics, government organizations, and industry. The organizers also welcomed timely and novel poster presentations and at least twelve outstanding poster presentations were selected for short oral talks. Among these were two posters from the COMBINE Project on standardized murine pneumonia model to evaluate antibiotic treatments and the variability in murine bacterial pneumonia models used to evaluate new antimicrobial drug candidates.

UNITE4TB webinar: Progress made to date in shortening TB treatment
2022-07-07 13:00 - 14:00 (Europe/Berlin) | Online
Recap of the third UNITE4TB webinar: Progress made to date in shortening TB treatment
UNITE4TB held its third public webinar on Thursday 7 July, with a focus on the recent changes in the World Health Organization (WHO) guidelines for the treatment of Tuberculosis (TB) and an evaluation of the evidence underpinning the shortening of TB treatment for both drug-sensitive and drug-resistant disease. The keynote speaker for the session was Dr. Patrick Phillips, UNITE4TB Consortium member from the University of California, San Francisco (UCSF) Center for Tuberculosis. In addition to the points mentioned above, Patrick’s presentation also addressed gaps in the evidence, and questions in need of further research. Attendees were provided with a comprehensive overview of the new, shorter treatments for drug-sensitive and drug-resistant TB, namely the 4-month rifapentine-moxifloxacin regimen and the 6-month bedaquiline-pretomanid-linezolid-moxifloxacin regimen respectively. They were taken through the key findings of the four key clinical trials: Study 31/A5349, NiX-TB, ZeNiX-TB, and TB-PRACTECAL whereby Dr. Phillips addressed the strengths and limitations of the evidence gathered in support of each of the regimens. He emphasized how this evidence is, for the most part, compelling, but gaps still exist that need to be addressed in subsequent studies.
The take-home message of the session: “We have seen unprecedented progress in the shortening of TB treatment in recent years, and it’s an exciting time to be in TB research. The importance of strong evidence is clear: strong evidence results in sound guidelines. Our TB patients need the best treatments available and deserve the highest quality of evidence,” Dr. Patrick Phillips, UCSF.
View webinar recording here

Gordon Research Conference on Drug Resistance
2022-06-26 - 2022-07-01 | Bryant University, 1150 Douglas Pike, Smithfield, RI, 02917, United States
The prosperity of the modern world is threatened by the emergence of drug resistant pathogens, pesticide-resistant insects and herbicide-resistant weeds. Novel investigational cancer drugs increase life expectancy, but fail when resistance develops. The same principles of evolution drive the development of resistance in all of these contexts, yet each field attacks the problem of resistance alone. The Drug Resistance Gordon Research Conference (DRGRC) provides a unique forum where scientists and physicians working in infectious diseases, cancer and agriculture come together to discuss common issues and share approaches with the conviction that general strategies to minimize resistance can be developed by working together.
As in previous years, the conference strives to recruit a broad array of disciplinary expertise, varying seniority, and wide geographic and cultural perspectives. The organizers are recruiting internationally recognized speakers from infectious disease, cancer and agriculture, including representatives from academics, government organizations, and industry. The organizers also welcome – and will seek out – timely and novel poster presentations and at least twelve outstanding poster presentations will be selected for short oral talks.

Vaccination as a strategy to combat Antimicrobial Resistance
2022-06-17 00:00 - 14:00 (Europe/Berlin) | Online
Vaccination programs are known to be effective to both promote the prudent use of antibiotics and to prevent the spread of AMR. JPIAMR, in partnership with the Medical Research Council and BactiVac Network, are holding a live webinar to identify opportunities and priorities for vaccine research from an immunological perspective to a wider translational context, in the field of antimicrobial resistance (AMR).
The objectives of the webinar are:

To identify ways in which vaccination could be used to curb AMR
To examine the remaining gaps in the vaccines for AMR research portfolio and discuss how to tackle these
To better understand current attitudes to vaccination programmes, following the COVID-19 pandemic
To scope gaps and priorities for the JPIAMR Strategic Research and Innovations Agenda

Read more and register to the webinar.
JPIAMR is in the process of updating the JPIAMR Strategic Research and Innovation Agenda, contributing to the development of the candidate One Health AMR Partnership. This activity will support this process by allowing us to collect gaps and needs in the area of bacterial resistance.

Public Webinar: How CARB-X Partners are Addressing the Global Health Threat of AMR
2022-06-09 15:00 - 15:30 (Europe/Berlin) | Online
A 30-minute public webinar will be held on June 9, 2022 at 09:00 AM EDT with representatives from CARB-X, BARDA, Wellcome and NIAID to discuss the global health issues of AMR, and how CARB-X and its partners are working together to address them.
The webinar celebrates a recent announcement in which BARDA and Wellcome have committed up to an additional US$370 million to CARB-X.
Attendance is free and open to the public.

New Perspectives on Bacterial Drug Resistance
2022-06-09 13:00 - 15:30 (Europe/Berlin) | Online
JPIAMR in partnership with the Medical Research Council (MRC UKRI) are hosting a workshop on antibiotic resistance, specifically looking for input from Early to Mid-Career Researchers.
Antibiotic resistance is prevalent in bacterial infections across the world, threatening many of the fundamentals of modern medicine. A huge amount of work and funding has been focussed on understanding antibiotic resistance and developing novel strategies to overcome this growing problem. The question is, where are the remaining research gaps in this area? We are asking Early to Mid-Career Researchers to give us their thoughts on this question as they move to future leadership positions to best focus future research to tackle antibiotic resistance.
If you think you might have an excellent idea of what remains to be studied in the field of antibiotic resistance, then please consider submitting an abstract. The committee will aim to bring together a broad range of perspectives which will then be discussed in smaller breakout rooms.
We are looking for a wide perspective as to where gaps remain, rather than a specific research presentation. We aim to encompass a broad range of perspectives and expertise, covering all One Heath settings and encourage more interdisciplinary outlooks. Our definition of an Early to Mid-Career Researcher encompasses PhD students, postdocs and junior faculty.
If you would like to submit an abstract, to present what you think are the funding gaps in antibacterial resistance research, then please return a completed abstract submission form by May 13th, 2022 to amr@mrc.ukri.org. The form can be downloaded in the right side menu.
Abstracts will be assessed by our Steering Committee and outcomes will be communicated by the 23rd of May 2022.
JPIAMR is in the process of updating the JPIAMR Strategic Research and Innovation Agenda, contributing to the development of the candidate One Health AMR Partnership. This activity will support to this process by allowing us to collect gaps and needs in the area of bacterial resistance.

COMBINE Expert Workshop on Monoclonal Antibodies for AMR Pathogens
2022-06-08 15:00 - 2022-06-09 18:00 (Europe/Berlin) | Online
In June 2022, the Paul-Ehrlich-Institut organised a two-day virtual expert workshop on behalf of the COMBINE project. The workshop aimed to address the challenges in developing monoclonal antibodies (mAbs) against antimicrobial resistance (AMR) pathogens, with a specific focus on ESCAPE pathogens (E. faecium, S. aureus, C. difficile, A. baumannii, P. aeruginosa, and Enterobacteriaceae). The workshop brought together 24 experts from industry, academia, public health, and regulatory bodies to discuss recurring issues and potential mitigation strategies.
Experts highlighted the distinct challenges in developing mAbs for therapeutic or prophylactic treatments. Different approaches in designing mAb targets were discussed, including directly targeting the bacteria or targeting virulence factors. The importance of robust efficacy data from animal models before initiating clinical testing was emphasised. The potential use of Immunoglobulin M mAbs and inhalation administration for lung infections was also discussed. In the translational session, the experts discussed the integration of various variables into physiologically-based pharmacokinetic models, such as inflammation, tissue distribution, bacterial growth, and clinically relevant markers. The clinical session focused on the challenges in human drug development for mAbs, drawing learnings from COVID-19 trials. Experts highlighted the importance of selecting the right primary endpoint, identifying the appropriate patient population, and having rapid diagnostics available for future studies. Potential solutions to increase the efficiency of clinical trials were also discussed, including adaptive trials, clinical trial networks, and meta-analyses of smaller trials.
Overall, the workshop provided an open forum for experts to discuss and prioritise the challenges in the development of mAbs against AMR pathogens. The insights gained from the workshop will guide future work within the COMBINE project, aiming to overcome bottlenecks in the preclinical and clinical development of mAbs against AMR. This is particularly important given the promising potential of mAbs in treating and preventing AMR infections, particularly those caused by ESCAPE pathogens.
Workshop report available here

6th AMR Conference 2022 - Novel Antimicrobials & AMR Diagnostics
2022-04-07 - 2022-04-08 | Congress Center Basel, Messeplatz 21, Basel, 4058, Switzerland
After two years of digital AMR Conferences, we will finally meet each other in person for the 6th AMR Conference 2022 in Basel, Switzerland. Looking forward to see you there! Sign up for our AMR newsletter to stay updated about the status of further planning as well as other AMR-related news.

AMR Accelerator Cross-project Meeting (AMR Accelerator Members Only)
2022-04-06 | Basel, Switzerland
The 3rd AMR Accelerator Cross-project Meeting for the AMR Accelerator community, a total of 9 projects, took place on 06 April 2022 in Basel, Switzerland.
Please find more details here and the final agenda below:

DOWNLOAD THE FULL PROGRAMME HERE

DOWNLOAD THE PRESENTATIONS HERE

Webinar: Tuberculosis, current status update from ongoing research collaborations within the AMR Accelerator (AMR Accelerator Members Only)
2022-03-09 15:00 - 16:30 (Europe/Berlin) | ONLINE WEBINAR, RI
About fifteen people attended this webinar which provided the most recent updates of ongoing TB research within the IMI AMR Accelerator. The following speakers addressed the challenges of their respective TB projects:

Michael Hoelscher (Medical University München) who gave an update and intro to UNITE4TB;
Santiago Ferrer-Bazaga (Universidad Carlos III Madrid) who discussed some challenges from ERA4TB;
Michel Pieren (BioVersys) who gave a clinical update from TRIC-TB.

These updated were followed by a panel discussion moderated by Frederik Deroose (Connecting Pharma), where some of these challenges were discussed in more detail, and some further opportunities for leveraging the TB focused initiatives have been discussed.

UNITE4TB Webinar Global Panel discussion on global burden of TB
2022-03-03 13:00 - 14:00 (Europe/Berlin) | ONLINE WEBINAR, RI
Recap of the first UNITE4TB webinar: Panel discussion on global burden of TB
On 03 March 2022, UNITE4TB held its first in a series of webinars being organized by project partners, Instituto de Saúde Pública da Universidade do Porto (ISPUP) and the European Respiratory Society (ERS). The session featured a presentation by Prof. Mario Raviglione of the University of Milan (Partner of UNITE4TB) on the global impact of Tuberculosis (TB). A former Director of the WHO Global Tuberculosis Programme, Prof4. Raviglione is one of the most prominent speakers in the field of TB. His presentation provided a thorough overview of the burden of TB, stressing the importance of a multi-sectoral approach to end TB that involves not only national TB programmes and global health care systems but also addresses health beyond health. Despite being treatable and preventable, TB still represents a major global health threat. With 1.5 million people dying and 10 million affected every year worldwide, TB is by far the leading cause of death from a single infectious agent. The emergence of the COVID-19 pandemic in 2019 and the current war in Ukraine have put at risk the progress made in past decades in decreasing the burden of TB. The proper functioning of health care services and TB control programmes are now being severely threatened. Dr. Raviglione’s presentation was followed by a panel discussion chaired by Prof. Dr. Raquel Duarte (ISPUP) and Prof. Dr. Christoph Lange (Research Center Borstel), together with three members of the UNITE4TB Young Investigator Group: Dr. Raquel Villar Hernández (Germans Trias i Pujol research Institute), Dr. Arash Ghodousi (Vita-Salute San Raffaele University) and Dr. Olha Konstantynovska (Kharkiv National University). The discussion raised key questions regarding the challenges and solutions of TB control globally. This was the start of a bi-monthly series of UNITE4TB webinars. The next session will soon be announced – stay tuned!

View webinar recording here.

REVIVE Webinar: New technologies and strategies to overcome the challenges of sexually transmitted infections
2022-01-26 14:00 - 15:30 (Europe/Berlin) | Online
Kicking off the new year with new webinars, GARD-P continues its successful REVIVE series in 2022. For this webinar, the following speakers will be included:
– Ranmini Kularatne, National Institute for Communicable Diseases (South Africa)
– Saiq Mullick, University of the Witwatersrand (South Africa)
– Francis Ndowa, International Union against STIs (Zimbabwe)
– Catherine Martin, University of the Witwatersrand (South Africa)

Moderators:
– Amir Schroufi, GARDP (South Africa)
– Remco Peters, The Foundation for Professional Development (South Africa)
The speakers will give the following presentations:
Presentation 1: Public health and emerging issues: Gaps and challenges in current surveillance activity AMR, surveillance systems, and groups at high risk of STI acquisition and resistance (Ranmini Kularatne)
Presentation 2: Implementation challenges: Treatment uptake, return for treatment, treatment completion, partner notification, health systems issues and M&E gaps (Saiqa Mullick)
Presentation 3: Clinical challenges: Syndromic management limitations, Limited treatment options, Management of treatment failures (Francis Ndowa)
Presentation 4: Patient perspective: DCE on service delivery preferences for STI care amongst youth in South Africa (Catherine Martin)
The presentations will be followed by a panel discussion with Teodora Wi (WHO), Nicola Low (University of Bern), Thato Chidarikire (NDH), Cecilia Ferreyra (FIND), Fernando Pascual Martinez (GARDP) and Sam Phiri (Partners in Hope Malawi).
Audience questions will be answered at the end of the webinar.
Date and time:
26 January 2022, 14:00-15:30 CET. Find more time zones here.
Register here for this live webinar:
https://attendee.gotowebinar.com/register/6821484907773344779?source=partners
